Management of residual mass in nonseminomatous germ cell tumors following chemotherapy

Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Po...

Full description

Bibliographic Details
Main Authors: Siamak Daneshmand, Hooman Djaladat, Craig Nichols
Format: Article
Language:English
Published: SAGE Publishing 2011-08-01
Series:Therapeutic Advances in Urology
Online Access:https://doi.org/10.1177/1756287211418721
Description
Summary:Advanced stage nonseminomatous testis cancer is commonly treated with chemotherapy and surgical resection. Patients with retroperitoneal residual masses >1cm following induction chemotherapy with normalized tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. Post chemotherapy retroperitoneal residual mass less than 1 cm with normal markers may be considered as complete response, although the possibility of residual teratoma and viable germ cell tumor are not definitively ruled out. Excellent long term disease free survival following surveillance may justify this option as the treatment of choice in this cohort of patients.
ISSN:1756-2872
1756-2880